By Colin Kellaher
Eli Lilly said an experimental drug nearly eliminated an inherited type of bad cholesterol at its highest dose in a mid-stage study.
Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein(a), or lp(a), met its primary endpoint, reducing lp(a) levels by an average of 93.9% over the 60- to 180-day period after treatment with the highest tested dose of 400 milligrams.
The Indianapolis drugmaker said study participants who received the 16-milligram and 96-milligram lepodisiran doses saw reductions of 40.8% and 75.2% in lp(a) levels, respectively.
About 20% of Americans have high levels of lp(a), which is genetic and has been linked to increased risk for heart attack, stroke and other cardiovascular diseases. There are currently no FDA-approved drugs to lower lp(a) levels.
Eli Lilly said it will continue to evaluate the potential benefits of lepodisiran in an ongoing Phase 3 study.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 31, 2025 06:56 ET (10:56 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。